


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:03Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406396" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406396</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmcneul</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">48</journal-id><journal-id journal-id-type="pmc-domain">bmcneul</journal-id><journal-title-group><journal-title>BMC Neurology</journal-title></journal-title-group><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406396</article-id><article-id pub-id-type="pmcid-ver">PMC12406396.1</article-id><article-id pub-id-type="pmcaid">12406396</article-id><article-id pub-id-type="pmcaiid">12406396</article-id><article-id pub-id-type="pmid">40898140</article-id><article-id pub-id-type="doi">10.1186/s12883-025-04172-x</article-id><article-id pub-id-type="publisher-id">4172</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Multiple sclerosis patients&#8217; journey delay in diagnosis and treatment: a multicenter study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Ragab</surname><given-names initials="S">Salma</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fouda</surname><given-names initials="BH">Basem Hamdy</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sarhan</surname><given-names initials="AA">Abdallah-Almamun</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abbas</surname><given-names initials="A">Azza</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hassan</surname><given-names initials="AM">Asmaa Mohamed</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Embaby</surname><given-names initials="A">Ahmed</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hashim</surname><given-names initials="NA">Noha Ali</given-names></name><address><email>n.hashim83@hotmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04a97mm30</institution-id><institution-id institution-id-type="GRID">grid.411978.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0578 3577</institution-id><institution>Neurology Department, Faculty of Medicine, </institution><institution>Kafrelsheikh University, </institution></institution-wrap>Kafr El-Sheikh, Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/016jp5b92</institution-id><institution-id institution-id-type="GRID">grid.412258.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9477 7793</institution-id><institution>Neurology Department, Faculty of Medicine, </institution><institution>Tanta University, </institution></institution-wrap>Tanta, Egypt </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/053g6we49</institution-id><institution-id institution-id-type="GRID">grid.31451.32</institution-id><institution-id institution-id-type="ISNI">0000 0001 2158 2757</institution-id><institution>Neurology Department, Faculty of Medicine, </institution><institution>Zagazig University, </institution></institution-wrap>Zagazig, Egypt </aff><aff id="Aff4"><label>4</label>Neurology Consultant, General Secretariat of Mental Health, Cairo, Egypt </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/053g6we49</institution-id><institution-id institution-id-type="GRID">grid.31451.32</institution-id><institution-id institution-id-type="ISNI">0000 0001 2158 2757</institution-id><institution>Internal Medicine Department, Faculty of Medicine, </institution><institution>Zagazig University, </institution></institution-wrap>Zagazig, Egypt </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/053g6we49</institution-id><institution-id institution-id-type="GRID">grid.31451.32</institution-id><institution-id institution-id-type="ISNI">0000 0001 2158 2757</institution-id><institution>Department of Neurology, Faculty of Medicine, </institution><institution>Zagazig University, </institution></institution-wrap>El-Sharkia, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478179</issue-id><elocation-id>377</elocation-id><history><date date-type="received"><day>6</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>1</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12883_2025_Article_4172.pdf"/><abstract id="Abs1"><sec><title>Objective</title><p id="Par1">To determine factors that contribute to delayed diagnosis and treatment of MS patients. Additionally, the study aimed to evaluate the correlation between diagnostic and therapeutic delay and disease outcome.</p></sec><sec><title>Methods</title><p id="Par2">The current cohort observational multicenter study was performed at neurology clinics in four cities in Egypt. In this study, 239 MS patients were enrolled. Multiple Sclerosis Severity Scale (MSSS) and Expanded Disability Status Scale (EDSS) were utilized to measure disease severity and disability, respectively. Lag times for diagnosis were calculated in months from the time of the first symptoms to the accurate diagnosis.</p></sec><sec><title>Results</title><p id="Par3">The results revealed that multiple important variables had a negative impact on the timely diagnosis, including the clinical type, as PPMS had longer delayed diagnoses versus RRMS/SPMS (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Conversely, the occurrence of sensory symptoms at disease onset is linked to prolonged diagnostic delay (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Multivariate logistic regression showed that young age, PPMS, and sensory symptoms were independently associated with delay in MS diagnosis. Patients initially sought medical assistance from ophthalmologists and neurologists, resulting in a significantly more delay in diagnosis (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). A statistically positive correlation exists between the time for diagnosis and deterioration of MS assessed by EDSS, MSSS, or PI (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). In addition, logistic regression analysis demonstrated that EDSS at diagnosis, delayed diagnosis, and illness duration were independently linked to MS severity (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p></sec><sec><title>Conclusion</title><p id="Par4">Many factors prolong the duration of MS diagnosis, including the age at disease onset, the delay in being referred from other medical specialties, and the presence of sensory symptoms at disease onset. Furthermore, MS delayed diagnosis and treatment leads to high disease disability with poor functional outcomes.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Multiple sclerosis</kwd><kwd>Diagnosis</kwd><kwd>Treatment</kwd><kwd>Diagnostic delay</kwd><kwd>Disease severity</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Multiple sclerosis (MS) is a chronic condition marked by the presence of inflammation, demyelination, and degeneration in the central nervous system. It is widely regarded as a primary factor contributing to neurological disabilities in young adults [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].</p><p id="Par6">MS is a heterogeneous disease characterized by a diverse range of symptoms. Its diagnosis is determined by established criteria that require evidence of dissemination in both time and space [<xref ref-type="bibr" rid="CR3">3</xref>]. MS has a preclinical stage with demyelinating plaques detected utilizing magnetic resonance imaging (radiologically isolated syndrome) [<xref ref-type="bibr" rid="CR4">4</xref>]. Clinically isolated conditions, relapsing-remitting, and progressive form are the three main stages of MS, occurring in nearly 90% of cases [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par7">In the initial phases of MS, inflammation significantly contributes to the progression of the condition and serves as the primary focus of disease-modifying medications [<xref ref-type="bibr" rid="CR6">6</xref>]. Furthermore, there is compelling data indicating that these medications enhance disease prognosis [<xref ref-type="bibr" rid="CR7">7</xref>]. The significance of early diagnosis has been emphasized in recommending early intervention, particularly in high-risk cases [<xref ref-type="bibr" rid="CR8">8</xref>]. A delay in diagnosis can restrict the range of treatment options and the chance for early intervention, which could result in irreversible consequences [<xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par8">The delay in diagnosing and initiating treatment may be partly attributed to the complex nature of the disease, which makes it challenging to meet the diagnostic criteria while ruling out other potential conditions [<xref ref-type="bibr" rid="CR10">10</xref>]. According to a prior study, the rate of misdiagnosis in MS cases is approximately 5&#8211;10% [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par9">It is crucial to examine the factors implicated in delayed diagnosis in MS patients, particularly in developing countries such as Egypt. Consequently, the current study was carried out to investigate the factors linked to the delayed MS diagnosis.</p></sec><sec id="Sec2"><title>Patients and methods</title><p id="Par10">This cohort observational multicenter study was carried out during the interval from January 2022 to August 2023. We included 239 subjects over the age of 18 years with clinically defined MS based on the 2017 McDonald criteria [<xref ref-type="bibr" rid="CR3">3</xref>]. We collected retrospective data from MS clinics in various places in Egypt, including El Gharbia, Kafr El Sheikh, Cairo, and El Sharkia. Therefore, it is highly likely that all MS patients in these clinics are included in the sample. Patients with unclear diagnoses or incomplete records were excluded from the study (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>).</p><p id="Par11">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Flowchart of patient selection</p></caption><graphic id="d33e321" position="float" orientation="portrait" xlink:href="12883_2025_4172_Fig1_HTML.jpg"/></fig>
</p><p id="Par12">All patient records were reviewed and scrutinized to collect data on sex, age, diagnosis time, the time of disease onset, and course of disease. MS onset was determined as the first occurrence of neurological impairments that indicate MS [<xref ref-type="bibr" rid="CR12">12</xref>]. The time of diagnosis was determined as the time when a neurologist officially established the diagnosis. The diagnostic delay in months was determined by subtracting the stated date of disease onset from the date of the definitive diagnosis of MS.</p><p id="Par13">The causes of delayed MS diagnosis were divided into two main factors: patient-related causes and medical-related causes. Patient-related causes include denial of symptoms or reluctance to seek medical assistance. Medical-related causes include insufficient knowledge or the lack of specialized centers as well as diagnostic facilities. We gathered this information through detailed patient histories obtained during structured interviews. This approach enabled us to document the timeline of symptom onset, initial medical consultations, and eventual diagnosis comprehensively. By directly engaging with patients, we could capture important contextual details, such as personal and systemic factors contributing to delays. While self-reported data can be influenced by recall bias, we mitigated this by using a structured interview format with specific prompts, ensuring accuracy and consistency. Where possible, we also cross-referenced patient accounts with medical records.</p><p id="Par14">The patients with MS were categorized into three groups according to their clinical course: primary progressive (PP-MS) (<italic toggle="yes">N</italic>&#8201;=&#8201;8), secondary progressive (SP-MS) (<italic toggle="yes">N</italic>&#8201;=&#8201;78), and relapsing-remitting (RR-MS) (<italic toggle="yes">N</italic>&#8201;=&#8201;153). The evaluation of clinical disability was conducted utilizing the Kurtzke EDSS [<xref ref-type="bibr" rid="CR13">13</xref>], whereas MS severity was assessed utilizing the MSSS, which is an algorithm that establishes a correlation between the EDSS scores in MS patients with comparable disease durations [<xref ref-type="bibr" rid="CR14">14</xref>]. Disease duration in our study is defined as the time from the onset of the first symptoms to the last available visit. The number of attacks was counted as the total number of relapses that occurred from the onset of symptoms to the last available visit. This includes all documented relapses during the patient&#8217;s disease course.</p></sec><sec id="Sec3"><title>Statistical analysis</title><p id="Par15">Collected data were statistically analyzed utilizing the Jamovi project (2022) (Version 2.3). Qualitative data was represented in the form of numbers and percentages (N. %), while quantitative data was presented as mean&#8201;&#177;&#8201;SD and median (IQR). Interferential statistics: The chi-square and Fisher&#8217;s exact tests were used for qualitative data analysis. In contrast, quantitative data with normal distribution were analyzed using the t-test and ANOVA tests. For skewed data, both Kruskal-Wallis and Mann-Whitney tests were used. The significance level, denoted as the P-value, can be categorized as follows: <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001 indicates high significance, <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05 indicates non-significance, and <italic toggle="yes">P</italic>&#8201;&#8804;&#8201;0.05 indicates significance. Pearson&#8217;s correlation was utilized to determine correlations between two continuous, normally distributed variables. Multiple linear regressions were employed to examine and determine the correlation between a quantitative variable and a set of independent variables.</p></sec><sec id="Sec4"><title>Results</title><p id="Par16">The sociodemographic and clinical variables related to the diagnosis procedure are displayed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>. The average period between the initial clinical symptoms and the diagnosis of MS was 14.01&#8201;&#177;&#8201;9.8 months (a median diagnostic delay of 14 months). Our study revealed that the delay in diagnosis was statistically longer in patients aged&#8201;&lt;&#8201;30 years compared to those aged&#8201;&#8805;&#8201;30 years (<italic toggle="yes">p</italic>&#8201;=&#8201;0.01). The mean age was 32 years (range: 16 to 59 years), and the mean age at diagnosis was 30 years (range: 15 to 46 years). The majority of subjects were females (69.5%; female/male ratio: 2.27). There were no significant differences between males and females in terms of the delay in diagnosis (<italic toggle="yes">p</italic>&#8201;=&#8201;0.726). No variation in diagnosis delays was found between patients according to their academic qualifications, residence, or employment state.</p><p id="Par17">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Sociodemographic and clinical characters of MS patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="2">Parameter</th><th align="left" rowspan="2" colspan="1">Total (239)<break/>(N %)</th><th align="left" colspan="2" rowspan="1">Time from onset of symptoms to Diagnosis (Months)</th><th align="left" rowspan="2" colspan="1">P value</th></tr><tr><th align="left" colspan="1" rowspan="1">Mean&#8201;&#177;&#8201;SD</th><th align="left" colspan="1" rowspan="1">Median (Range)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Age of onset</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;30 y</td><td align="left" colspan="1" rowspan="1">100 (41.8%)</td><td align="left" colspan="1" rowspan="1">15.29&#8201;&#177;&#8201;11.52</td><td align="left" colspan="1" rowspan="1">12 (2&#8211;42)</td><td char="." align="char" rowspan="2" colspan="1">
<bold>0.01</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;30 y</td><td align="left" colspan="1" rowspan="1">139 (58.2%)</td><td align="left" colspan="1" rowspan="1">12.09&#8201;&#177;&#8201;9.92</td><td align="left" colspan="1" rowspan="1">11 (1&#8211;38)</td></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">166 (69.5%)</td><td align="left" colspan="1" rowspan="1">14&#8201;&#177;&#8201;11</td><td align="left" colspan="1" rowspan="1">12 (1&#8211;42)</td><td char="." align="char" rowspan="2" colspan="1">0.726</td></tr><tr><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">73 (30.5%)</td><td align="left" colspan="1" rowspan="1">14&#8201;&#177;&#8201;10</td><td align="left" colspan="1" rowspan="1">12 (1&#8211;38)</td></tr><tr><td align="left" rowspan="2" colspan="1">Residence</td><td align="left" colspan="1" rowspan="1">Rural</td><td align="left" colspan="1" rowspan="1">102 (42.7%)</td><td align="left" colspan="1" rowspan="1">14&#8201;&#177;&#8201;10</td><td align="left" colspan="1" rowspan="1">12 (1&#8211;39)</td><td char="." align="char" rowspan="2" colspan="1">0.971</td></tr><tr><td align="left" colspan="1" rowspan="1">Urban</td><td align="left" colspan="1" rowspan="1">137 (57.3%)</td><td align="left" colspan="1" rowspan="1">14&#8201;&#177;&#8201;11</td><td align="left" colspan="1" rowspan="1">12 (1&#8211;42)</td></tr><tr><td align="left" rowspan="3" colspan="1">Education</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;12y</td><td align="left" colspan="1" rowspan="1">69 (28.9%)</td><td align="left" colspan="1" rowspan="1">14&#8201;&#177;&#8201;12</td><td align="left" colspan="1" rowspan="1">9 (1&#8211;39)</td><td char="." align="char" rowspan="3" colspan="1">0.635</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;12y</td><td align="left" colspan="1" rowspan="1">152 (63.6%)</td><td align="left" colspan="1" rowspan="1">14&#8201;&#177;&#8201;10</td><td align="left" colspan="1" rowspan="1">12 (1&#8211;42)</td></tr><tr><td align="left" colspan="1" rowspan="1">Illiterate</td><td align="left" colspan="1" rowspan="1">18 (7.5%)</td><td align="left" colspan="1" rowspan="1">16&#8201;&#177;&#8201;12</td><td align="left" colspan="1" rowspan="1">17 (2&#8211;38)</td></tr><tr><td align="left" rowspan="4" colspan="1">Employment status</td><td align="left" colspan="1" rowspan="1">unemployed</td><td align="left" colspan="1" rowspan="1">88 (36.8%)</td><td align="left" colspan="1" rowspan="1">15&#8201;&#177;&#8201;12</td><td align="left" colspan="1" rowspan="1">11 (1&#8211;39)</td><td char="." align="char" rowspan="4" colspan="1">0.1</td></tr><tr><td align="left" colspan="1" rowspan="1">Retired</td><td align="left" colspan="1" rowspan="1">33 (13.8%)</td><td align="left" colspan="1" rowspan="1">16&#8201;&#177;&#8201;10</td><td align="left" colspan="1" rowspan="1">16 (2&#8211;37)</td></tr><tr><td align="left" colspan="1" rowspan="1">Student</td><td align="left" colspan="1" rowspan="1">20 (8.4%)</td><td align="left" colspan="1" rowspan="1">9&#8201;&#177;&#8201;8</td><td align="left" colspan="1" rowspan="1">6 (1&#8211;27)</td></tr><tr><td align="left" colspan="1" rowspan="1">Working</td><td align="left" colspan="1" rowspan="1">98 (41.0%)</td><td align="left" colspan="1" rowspan="1">14&#8201;&#177;&#8201;10</td><td align="left" colspan="1" rowspan="1">12 (1&#8211;42)</td></tr><tr><td align="left" rowspan="2" colspan="1">Marital status</td><td align="left" colspan="1" rowspan="1">Married</td><td align="left" colspan="1" rowspan="1">169 (70.7%)</td><td align="left" colspan="1" rowspan="1">14&#8201;&#177;&#8201;11</td><td align="left" colspan="1" rowspan="1">12 (1&#8211;42)</td><td char="." align="char" rowspan="2" colspan="1">0.505</td></tr><tr><td align="left" colspan="1" rowspan="1">Single</td><td align="left" colspan="1" rowspan="1">70 (29.3%)</td><td align="left" colspan="1" rowspan="1">14&#8201;&#177;&#8201;11</td><td align="left" colspan="1" rowspan="1">12 (1&#8211;39)</td></tr><tr><td align="left" rowspan="3" colspan="1">Family history</td><td align="left" colspan="1" rowspan="1">Absent</td><td align="left" colspan="1" rowspan="1">210 (87.9%)</td><td align="left" colspan="1" rowspan="1">14&#8201;&#177;&#8201;11</td><td align="left" colspan="1" rowspan="1">12 (1&#8211;42)</td><td char="." align="char" rowspan="3" colspan="1">0.547</td></tr><tr><td align="left" colspan="1" rowspan="1">History of MS</td><td align="left" colspan="1" rowspan="1">10 (4.2%)</td><td align="left" colspan="1" rowspan="1">9&#8201;&#177;&#8201;6</td><td align="left" colspan="1" rowspan="1">11 (1&#8211;18)</td></tr><tr><td align="left" colspan="1" rowspan="1">Other autoimmune</td><td align="left" colspan="1" rowspan="1">19 (7.9%)</td><td align="left" colspan="1" rowspan="1">15&#8201;&#177;&#8201;11</td><td align="left" colspan="1" rowspan="1">12 (2&#8211;38)</td></tr><tr><td align="left" rowspan="2" colspan="1">Onset of illness</td><td align="left" colspan="1" rowspan="1">Before 2017</td><td align="left" colspan="1" rowspan="1">103 (43.1%)</td><td align="left" colspan="1" rowspan="1">16.9&#8201;&#177;&#8201;11.3</td><td align="left" colspan="1" rowspan="1">14 (1&#8211;42)</td><td align="left" rowspan="2" colspan="1">
<bold>0.003</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">After 2017</td><td align="left" colspan="1" rowspan="1">136 (56.9%)</td><td align="left" colspan="1" rowspan="1">12.4&#8201;&#177;&#8201;9.02</td><td align="left" colspan="1" rowspan="1">12 (1&#8211;38)</td></tr><tr><td align="left" rowspan="2" colspan="1">Type of MS</td><td align="left" colspan="1" rowspan="1">PPMS</td><td align="left" colspan="1" rowspan="1">8 (3.3%)</td><td align="left" colspan="1" rowspan="1">19&#8201;&#177;&#8201;13</td><td align="left" colspan="1" rowspan="1">16 (6&#8211;38)</td><td char="." align="char" rowspan="2" colspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">RRMS/SPMS</td><td align="left" colspan="1" rowspan="1">231 (96.7%)</td><td align="left" colspan="1" rowspan="1">12&#8201;&#177;&#8201;6</td><td align="left" colspan="1" rowspan="1">10 (5&#8211;35)</td></tr><tr><td align="left" rowspan="6" colspan="1">Initial assessed by</td><td align="left" colspan="1" rowspan="1">Neurologist</td><td align="left" colspan="1" rowspan="1">117 (50.2%)</td><td align="left" colspan="1" rowspan="1">11&#8201;&#177;&#8201;10</td><td align="left" colspan="1" rowspan="1">9 (1&#8211;39)</td><td char="." align="char" rowspan="6" colspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Ophthalmologist</td><td align="left" colspan="1" rowspan="1">33 (14.2%)</td><td align="left" colspan="1" rowspan="1">9&#8201;&#177;&#8201;7</td><td align="left" colspan="1" rowspan="1">7 (1&#8211;24)</td></tr><tr><td align="left" colspan="1" rowspan="1">Orthopedic</td><td align="left" colspan="1" rowspan="1">33 (14.2%)</td><td align="left" colspan="1" rowspan="1">19&#8201;&#177;&#8201;10</td><td align="left" colspan="1" rowspan="1">18 (3&#8211;39)</td></tr><tr><td align="left" colspan="1" rowspan="1">Internal medicine</td><td align="left" colspan="1" rowspan="1">5 (2.1%)</td><td align="left" colspan="1" rowspan="1">19&#8201;&#177;&#8201;3</td><td align="left" colspan="1" rowspan="1">19 (16&#8211;24)</td></tr><tr><td align="left" colspan="1" rowspan="1">Neurosurgery</td><td align="left" colspan="1" rowspan="1">31 (13.3%)</td><td align="left" colspan="1" rowspan="1">20&#8201;&#177;&#8201;12</td><td align="left" colspan="1" rowspan="1">20 (4&#8211;39)</td></tr><tr><td align="left" colspan="1" rowspan="1">Family physician</td><td align="left" colspan="1" rowspan="1">14 (6.0%)</td><td align="left" colspan="1" rowspan="1">19&#8201;&#177;&#8201;14</td><td align="left" colspan="1" rowspan="1">15 (3&#8211;42)</td></tr><tr><td align="left" rowspan="3" colspan="1">Reasons of diagnosis delay</td><td align="left" colspan="1" rowspan="1">Medical cause</td><td align="left" colspan="1" rowspan="1">102 (42.7%)</td><td align="left" colspan="1" rowspan="1">13.55&#8201;&#177;&#8201;9.76</td><td align="left" colspan="1" rowspan="1">11 (4&#8211;38)</td><td char="." align="char" rowspan="3" colspan="1">
<bold>0.004*</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Patient cause</td><td align="left" colspan="1" rowspan="1">118 (49.4%)</td><td align="left" colspan="1" rowspan="1">9.42&#8201;&#177;&#8201;11.7</td><td align="left" colspan="1" rowspan="1">4 (1&#8211;39)</td></tr><tr><td align="left" colspan="1" rowspan="1">Patient/Medical cause</td><td align="left" colspan="1" rowspan="1">19 (7.9%)</td><td align="left" colspan="1" rowspan="1">16.63&#8201;&#177;&#8201;11.71</td><td align="left" colspan="1" rowspan="1">14.5 (1&#8211;42)</td></tr><tr><td align="left" rowspan="4" colspan="1">Center</td><td align="left" colspan="1" rowspan="1">Cairo</td><td align="left" colspan="1" rowspan="1">53 (22.2%)</td><td align="left" colspan="1" rowspan="1">12.43&#8201;&#177;&#8201;11.33</td><td align="left" colspan="1" rowspan="1">8 (1&#8211;42)</td><td align="left" rowspan="4" colspan="1">0.26</td></tr><tr><td align="left" colspan="1" rowspan="1">Kafr Elsheikh</td><td align="left" colspan="1" rowspan="1">52 (21.8%)</td><td align="left" colspan="1" rowspan="1">9.75&#8201;&#177;&#8201;7.33</td><td align="left" colspan="1" rowspan="1">8.5 (1&#8211;29)</td></tr><tr><td align="left" colspan="1" rowspan="1">Tanta</td><td align="left" colspan="1" rowspan="1">74 (31%)</td><td align="left" colspan="1" rowspan="1">16.41&#8201;&#177;&#8201;13.6</td><td align="left" colspan="1" rowspan="1">13 (1&#8211;39)</td></tr><tr><td align="left" colspan="1" rowspan="1">Zagazig</td><td align="left" colspan="1" rowspan="1">60 (25.1%)</td><td align="left" colspan="1" rowspan="1">10.55&#8201;&#177;&#8201;6.36</td><td align="left" colspan="1" rowspan="1">9 (2&#8211;27)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Data were reported as mean&#8201;&#177;&#8201;SD. <sup>b</sup> Data were reported as number (%). <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 is considered significant. <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05 is considered non-significant. RRMS, Relapsing-remitting MS; SPMS, Secondary progressive MS; PPMS, Primary progressive MS</p></table-wrap-foot></table-wrap>
</p><p id="Par18">According to MS classification, cases with PPMS experienced a substantially longer time to diagnosis (19&#8201;&#177;&#8201;13 months) compared to other MS clinical phenotypes (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p><p id="Par19">Our investigation found no substantial variation in the diagnostic delay between the four studied centers (<italic toggle="yes">p</italic>&#8201;=&#8201;0.26).</p><p id="Par20">Before 2017, the mean duration of delay in diagnosis of MS was 16.9&#8201;&#177;&#8201;11.3 months, significantly higher than those diagnosed after 2017 (<italic toggle="yes">p</italic>&#8201;=&#8201;003).</p><p id="Par21">Among our patients, the first health professional consulted was a neurologist (50%), an ophthalmologist (14%), an orthopedic surgeon (14%), a neurosurgery (13%), a family physician (6%), and an internal medicine specialist (2%). Patients who were initially evaluated by an ophthalmologist or a neurologist had a considerably shorter time to diagnosis compared to those examined by other medical specialties (9&#8201;&#177;&#8201;7 months and 11&#8201;&#177;&#8201;10 months, respectively; <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Most causes of delayed diagnosis are a combination of patient and medical causes (<italic toggle="yes">p</italic>&#8201;=&#8201;0.004).</p><p id="Par22">The most prevalent initial clinical symptom was optic symptoms, occurring in 33.5% of cases. This was followed by pyramidal symptoms in 30.5% of cases, sensory symptoms in 24.3% of cases, brainstem/cerebellar symptoms in 11.3% of cases, sphincteric symptoms (4.2%), and mental symptoms in 0.4% of cases (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par23">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Initial symptoms and diagnostic delay</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2" rowspan="1"/><th align="left" colspan="1" rowspan="1">Total (<italic toggle="yes">N</italic> %)</th><th align="left" colspan="1" rowspan="1">Time from onset of symptoms to Diagnosis (Months)<break/>Mean&#8201;&#177;&#8201;SD</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="6" colspan="1">Type of First Symptoms</td><td align="left" colspan="1" rowspan="1">Optic</td><td char="." align="char" colspan="1" rowspan="1">80 (33.5%)</td><td align="left" colspan="1" rowspan="1">8&#8201;&#177;&#8201;7</td><td char="." align="char" rowspan="6" colspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">pyramidal</td><td char="." align="char" colspan="1" rowspan="1">73 (30.5%)</td><td align="left" colspan="1" rowspan="1">14&#8201;&#177;&#8201;10</td></tr><tr><td align="left" colspan="1" rowspan="1">sensory</td><td char="." align="char" colspan="1" rowspan="1">58 (24.3%)</td><td align="left" colspan="1" rowspan="1">24&#8201;&#177;&#8201;11</td></tr><tr><td align="left" colspan="1" rowspan="1">Brainstem/cerebellar</td><td char="." align="char" colspan="1" rowspan="1">27 (11.3%)</td><td align="left" colspan="1" rowspan="1">10&#8201;&#177;&#8201;4</td></tr><tr><td align="left" colspan="1" rowspan="1">mental symptoms</td><td char="." align="char" colspan="1" rowspan="1">1 (0.4%)</td><td align="left" colspan="1" rowspan="1">9</td></tr><tr><td align="left" colspan="1" rowspan="1">sphincteric</td><td char="." align="char" colspan="1" rowspan="1">10 (4.2%)</td><td align="left" colspan="1" rowspan="1">10&#8201;&#177;&#8201;3</td></tr><tr><td align="left" rowspan="3" colspan="1">Number of relapses before diagnosis</td><td align="left" colspan="1" rowspan="1">0&#8211;1</td><td char="." align="char" colspan="1" rowspan="1">3 (1.3%)</td><td align="left" colspan="1" rowspan="1">22&#8201;&#177;&#8201;16</td><td char="." align="char" rowspan="3" colspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">2&#8211;3</td><td char="." align="char" colspan="1" rowspan="1">114 (47.7%)</td><td align="left" colspan="1" rowspan="1">18&#8201;&#177;&#8201;10</td></tr><tr><td align="left" colspan="1" rowspan="1">&gt;&#8201;3</td><td char="." align="char" colspan="1" rowspan="1">122 (51.0%)</td><td align="left" colspan="1" rowspan="1">10&#8201;&#177;&#8201;9</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Data were reported as mean&#8201;&#177;&#8201;SD. <sup>b</sup> Data were reported as number (%)., <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 is considered significant. <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05 is considered non-significant</p></table-wrap-foot></table-wrap>
</p><p id="Par24">Patients who exhibited visual impairment were diagnosed at an earlier stage. Furthermore, individuals who had a sensory deficit experienced the most significant delay in diagnosis (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001). Furthermore, patients with low relapses had a statistically significant longer duration before the diagnosis (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p><p id="Par25">Figures (<xref rid="Fig2" ref-type="fig">2</xref> &amp; <xref rid="Fig3" ref-type="fig">3</xref>) show a statistically positive correlation between diagnostic delay and a more severe disease deterioration as assessed by EDSS and MSSS (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), respectively.</p><p id="Par26">The multivariate logistic regression demonstrated that age at disease onset&#8201;&lt;&#8201;30 years and sensory symptoms at onset are more likely to experience a prolonged diagnostic delay (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par27">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Multivariate logistic regression for lower time until diagnosis (&lt;&#8201;14 month)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="left" rowspan="2" colspan="1"/><th align="left" colspan="2" rowspan="1">Univariate analysis</th><th align="left" rowspan="2" colspan="1">P value</th><th align="left" colspan="2" rowspan="1">Multivariate analysis</th><th align="left" rowspan="2" colspan="1">P value</th></tr><tr><th align="left" colspan="1" rowspan="1">OR</th><th align="left" colspan="1" rowspan="1">95% CI</th><th align="left" colspan="1" rowspan="1">OR</th><th align="left" colspan="1" rowspan="1">95% CI</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Sex</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" rowspan="2" colspan="1">0.39</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">0.78</td><td align="left" colspan="1" rowspan="1">(0.45&#8211;1.37)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Age</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;30years</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" rowspan="2" colspan="1">
<bold>0.04*</bold>
</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&lt;&#8201;30 years</td><td align="left" colspan="1" rowspan="1">0.46</td><td align="left" colspan="1" rowspan="1">(0.21&#8211;0.99)</td><td align="left" colspan="1" rowspan="1">0.44</td><td align="left" colspan="1" rowspan="1">(0.2&#8211;0.98)</td><td align="left" colspan="1" rowspan="1">
<bold>0.04</bold>
</td></tr><tr><td align="left" rowspan="3" colspan="1">Education</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;12 y</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8805;&#8201;12 y</td><td align="left" colspan="1" rowspan="1">1.24</td><td align="left" colspan="1" rowspan="1">(0.69&#8211;2.22)</td><td align="left" colspan="1" rowspan="1">0.47</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Illiterate</td><td align="left" colspan="1" rowspan="1">2.57</td><td align="left" colspan="1" rowspan="1">(1.59&#8211;4.19)</td><td align="left" colspan="1" rowspan="1">
<bold>0.03*</bold>
</td><td align="left" colspan="1" rowspan="1">0.74</td><td align="left" colspan="1" rowspan="1">(0.41&#8211;1.33)</td><td align="left" colspan="1" rowspan="1">0.31</td></tr><tr><td align="left" rowspan="2" colspan="1">MS Phenotypes</td><td align="left" colspan="1" rowspan="1">RRMS/SPMS</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">PPMS</td><td align="left" colspan="1" rowspan="1">4.57</td><td align="left" colspan="1" rowspan="1">(1.02&#8211;20.52)</td><td align="left" colspan="1" rowspan="1">
<bold>0.05*</bold>
</td><td align="left" colspan="1" rowspan="1">13.9</td><td align="left" colspan="1" rowspan="1">(6.3&#8211;30.66)</td><td align="left" colspan="1" rowspan="1">
<bold>0.02</bold>
</td></tr><tr><td align="left" rowspan="5" colspan="1">First symptoms</td><td align="left" colspan="1" rowspan="1">Optic</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Motor</td><td align="left" colspan="1" rowspan="1">0.35</td><td align="left" colspan="1" rowspan="1">(0.12&#8211;1.79)</td><td align="left" colspan="1" rowspan="1">
<bold>0.02*</bold>
</td><td align="left" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">(0.98&#8211;1.03)</td><td align="left" colspan="1" rowspan="1">0.6</td></tr><tr><td align="left" colspan="1" rowspan="1">Sensory</td><td align="left" colspan="1" rowspan="1">0.03</td><td align="left" colspan="1" rowspan="1">(0.009&#8211;0.12)</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001*</bold>
</td><td align="left" colspan="1" rowspan="1">0.04</td><td align="left" colspan="1" rowspan="1">(0.009&#8211;0.18)</td><td align="left" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">Ataxia</td><td align="left" colspan="1" rowspan="1">0.54</td><td align="left" colspan="1" rowspan="1">(0.28&#8211;1.07)</td><td align="left" colspan="1" rowspan="1">0.08</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Psychiatric</td><td align="left" colspan="1" rowspan="1">0.68</td><td align="left" colspan="1" rowspan="1">(0.007&#8211;1.68)</td><td align="left" colspan="1" rowspan="1">0.18</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p>OR: odds ratio; 95%CI: 95% confidence interval, Ref: category versus the one is making comparisons, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 is considered significant. <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05 is considered non-significant; RRMS, Relapsing-remitting MS; SPMS, Secondary progressive MS; PPMS, Primary progressive MS</p></table-wrap-foot></table-wrap>
</p><p id="Par28">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Linear regression analysis for disease severity measured by MSSS</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables</th><th align="left" colspan="1" rowspan="1">Estimate</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Age of onset</italic>
</td><td char="." align="char" colspan="1" rowspan="1">0.0186</td><td char="." align="char" colspan="1" rowspan="1">0.015</td><td char="." align="char" colspan="1" rowspan="1">0.220</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Number of attacks</italic>
</td><td char="." align="char" colspan="1" rowspan="1">0.1023</td><td char="." align="char" colspan="1" rowspan="1">0.046</td><td char="." align="char" colspan="1" rowspan="1">0.028</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">EDSS At time of diagnosis</italic>
</td><td char="." align="char" colspan="1" rowspan="1">2.0011</td><td char="." align="char" colspan="1" rowspan="1">0.13</td><td char="." align="char" colspan="1" rowspan="1">
<bold>&lt;&#8201;0.001</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">Duration from diagnosis to treatment (months)</italic>
</td><td char="." align="char" colspan="1" rowspan="1">0.107</td><td char="." align="char" colspan="1" rowspan="1">0.064</td><td char="." align="char" colspan="1" rowspan="1">
<bold>0.009</bold>
</td></tr></tbody></table><table-wrap-foot><p>SE, Standard error. <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05 is considered significant. <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05 is considered non-significant. EDSS, Expanded Disability Status Scale</p></table-wrap-foot></table-wrap>
</p><p id="Par29">Finally, linear regression depicted results in Table <xref rid="Tab4" ref-type="table">4</xref> reveal that EDSS at the time of diagnosis, delayed diagnosis, and illness duration are independently associated with MS severity.</p></sec><sec id="Sec5"><title>Discussion</title><p id="Par30">Given the increasing incidence and prevalence of MS in recent times, the effects of disease activity and the resulting accumulated damage significantly result in a decline in quality of life. Diagnostic delays resulting from diagnostic uncertainty can cause delays in initiating therapy. Early MS diagnosis is crucial in order to minimize the impact of disability and the associated financial burden. Therefore, we conducted a study to examine the duration between the onset of clinical symptoms and MS diagnosis and determine the potential factors that can lead to a diagnostic delay in a cohort of MS patients in Egypt.</p><p id="Par31">The findings of our investigation indicate that the average time between the emergence of symptoms and the diagnosis of MS was 14 months. Our findings follow those reported by Khodaie et al. [<xref ref-type="bibr" rid="CR15">15</xref>] who reported the meantime interval of diagnosis was 13.42 months. This duration was shorter than the durations reported in the studies done by Ghiasian et al. [<xref ref-type="bibr" rid="CR16">16</xref>] (18.23 months), Thormann et al. [<xref ref-type="bibr" rid="CR17">17</xref>] (47.5 months) and Bahou et al. [<xref ref-type="bibr" rid="CR18">18</xref>] (23 months). and longer than the study by Aires et al. [<xref ref-type="bibr" rid="CR19">19</xref>] (9 months) and Mobasheri et al. [<xref ref-type="bibr" rid="CR20">20</xref>] (7 months). According to a recent study conducted in upper Egypt, around 49% of patients with MS had a diagnosis that was delayed by more than three months [<xref ref-type="bibr" rid="CR21">21</xref>]. The National Institute for Clinical Excellence (NICE) recommended that MS be diagnosed within three months at the latest. This means that there should be no more than six weeks between the onset of MS symptoms and the first consultation with a neurologist, followed by an additional six weeks until all necessary investigations are completed [<xref ref-type="bibr" rid="CR22">22</xref>]. Differences between countries may be due to differences in referral processes, utilizing different diagnostic methods, the level of health literacy among different ethnic groups, and the accessibility and strength of specialized healthcare facilities. According to the Multiple Sclerosis International Federation Atlas of MS, low-income countries are more likely to report at least one major barrier to early diagnosis of MS than high/upper middle-income countries [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par32">Regarding the age at onset, 58.2% of our patients were older than 30 years, and the diagnostic delay was more common in patients under 30 years. This finding aligns with Khedr et al. [<xref ref-type="bibr" rid="CR21">21</xref>] and Tohamy et al. [<xref ref-type="bibr" rid="CR24">24</xref>] studies on Egyptian MS patients. Furthermore, Marrie et al. [<xref ref-type="bibr" rid="CR25">25</xref>] reported that younger age was associated with diagnostic delay. Additionally, C&#225;rdenas-Robledo et al. [<xref ref-type="bibr" rid="CR26">26</xref>] reported no link between age and diagnostic delay. On the other hand, Patti et al. [<xref ref-type="bibr" rid="CR27">27</xref>] found that older age at MS onset was a risk factor for delay in diagnosis. The difference in results could be due to differences in MS prevalence and risk factors leading to variability in the age at onset in different countries or even disparities in access to diagnostic facilities [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par33">Based on the data analysis, this study showed that the mean delay duration in the diagnosis of MS before 2017 was significantly higher than that after 2017. This may indicate that the time to diagnosis has gradually decreased over the study period due to the improvement in diagnostic criteria [<xref ref-type="bibr" rid="CR28">28</xref>]. Hosseinnataj et al. [<xref ref-type="bibr" rid="CR29">29</xref>] noted that the EDSS scores showed significant differences before and after 2017. This suggests that there may have been improvements in the diagnostic process or changes in patient characteristics over time. Hence, the rise in prevalence in recent years could be attributed, in part, to advancements in diagnostic techniques, including the 3 Tesla brain MRI, which has been more accessible in recent times. Additionally, there is now an ability to identify younger patients and individuals with less severe conditions who are living longer with the condition.</p><p id="Par34">Regarding residence, there was no notable disparity in the delay of MS diagnosis between patients from the four different centers or patients living in rural or urban areas. In contrast, Ghiasian et al. [<xref ref-type="bibr" rid="CR16">16</xref>] illustrated that the average time between symptoms onset and diagnosis was longer in villagers than in citizens. Internationally, rural dwellings have been reported as a cause of delay in diagnosis of tuberculosis, cancer, congenital hearing loss, and dementia [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. This can be attributed to factors such as distance travel, patients&#8217; tendency to seek alternative medical care first [<xref ref-type="bibr" rid="CR32">32</xref>], and the low level of education [<xref ref-type="bibr" rid="CR33">33</xref>]. The absence of disparity in diagnostic delay between rural and urban areas in our study can be attributed to the swift and substantial decline in functional ability and physical autonomy experienced by MS patients, which encourages them to seek medical assistance. This is further facilitated by the presence of high-quality healthcare services in Egypt, as well as the collaboration between universities, research centers, and general hospitals.</p><p id="Par35">With regard to education level, there were no substantial differences between subjects with different levels of education and delays in diagnosis. This finding is compatible with those of Khedr et al. [<xref ref-type="bibr" rid="CR21">21</xref>] and Aires et al. [<xref ref-type="bibr" rid="CR19">19</xref>]. In contrast, a previous study by Ghiasian et al. [<xref ref-type="bibr" rid="CR16">16</xref>] reported that illiterate patients experience greater delay in seeking treatment after the onset of symptoms than illiterate patients.</p><p id="Par36">There is no evidence to suggest that sex, employment status, or family history of MS are linked to a delay in MS diagnosis, which is consistent with a number of prior studies [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Eccles [<xref ref-type="bibr" rid="CR35">35</xref>] suggested that the gender correlations of MS increase the probability of its diagnosis in women and decrease the likelihood of MS being detected when comparable symptoms and signs occur in males.</p><p id="Par37">Theoretically, it was hypothesized that having a partner can detect early symptoms and encourage early treatment, thus reducing the time needed for diagnosis. However, we observed no substantial disparity in the average duration between the diagnosis of MS and marital status. There is a limited number of studies examining this aspect, but these findings contradict the study conducted by Ghiasian et al. [<xref ref-type="bibr" rid="CR16">16</xref>], which found that married patients experienced a delay in diagnosis compared to single patients.</p><p id="Par38">Approximately 50% of the participants included in this study were initially examined by a non-neurologist. In contrast, patients first examined by an ophthalmologist and a neurologist had a significantly shorter diagnosis time than those examined by another medical specialty. In concordance with two Egyptian studies, the ophthalmologist is the most common non-neurology specialty first seen by MS patients [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Previous research has indicated that the period between symptoms onset and the first medical consultation is the main factor contributing to the delay in diagnosis [<xref ref-type="bibr" rid="CR4">4</xref>]. Kaisey and Solomon [<xref ref-type="bibr" rid="CR36">36</xref>] highlight various factors that contribute to the challenges in diagnosing MS. These include a lack of awareness among healthcare providers regarding early symptoms of MS and difficulties in applying the established diagnostic criteria correctly. These factors can lead to both misdiagnosis and delays in diagnosis.</p><p id="Par39">Although we do not know exactly where the delay occurs, it may be due to lack of knowledge about MS by other medical specialties, the time it takes for MS patient to seek medical care. MS, like other diseases, can be challenging to identify in its early stages, and there are several diseases and syndromes that may appear comparable to it. Moreover, numerous studies have demonstrated that the primary cause of the delay in diagnosing MS is the failure to recognize specific symptoms, which frequently results in misdiagnosis [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Our study revealed that 42.7% of the patients were given an inaccurate previous diagnosis, resulting in a prolonged delay in MS diagnosis. The complexity of this condition, characterized by multiple symptoms, often poses challenges in diagnosing it, particularly for individuals unfamiliar with it. In a multicenter study evaluating the knowledge of neurologists on MS, P&#233;loquin et al. [<xref ref-type="bibr" rid="CR39">39</xref>] found that 27% of the participants had either no understanding or only a rudimentary understanding of the latest diagnostic criteria for MS. Additionally, over one-third of the participants had either no knowledge or only a rudimentary knowledge of atypical presentations of MS. Therefore, it is essential for the general public, primary care providers, and neurologists to have a thorough understanding of MS symptoms and diagnosis.</p><p id="Par40">Our findings indicate that patients with PPMS experienced a longer diagnostic delay compared to those with RRMS, which aligns with the findings of Kingwell et al. [<xref ref-type="bibr" rid="CR9">9</xref>] and Aires et al. [<xref ref-type="bibr" rid="CR19">19</xref>] Khodaie et al. [<xref ref-type="bibr" rid="CR15">15</xref>]. PPMS is characterized by a limited number of relapses and a gradual worsening of disability over time, which makes it difficult to differentiate from other conditions. In addition, patients typically experience the onset of symptoms at an advanced age, and the presence of increasing paraparesis is a prevalent characteristic that poses challenges in the diagnostic process [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par41">From a clinical perspective, vision problems were the predominant early symptom observed in patients with MS, which aligns with the findings of the most recent MS registry of Egyptian patients [<xref ref-type="bibr" rid="CR24">24</xref>]. The involvement of the optic nerve was found to have a marked correlation with a short delay in diagnosis. This is because when this symptom occurs, consultation with specialists in neurology or ophthalmology is required, which leads to an early and rapid diagnosis.</p><p id="Par42">Optic neuritis was shown to be correlated with a reduced time to MS diagnosis, as indicated by the findings of Fernandez et al. [<xref ref-type="bibr" rid="CR4">4</xref>] and Ghiasian et al. [<xref ref-type="bibr" rid="CR16">16</xref>]. Conversely, in the Canadian and Danish groups, optic neuritis was linked to a longer period of time before diagnosis due to the symptoms rapidly resolving [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par43">In this study, the sensory deficit was associated with a longer diagnostic delay, which is consistent with the results of Aires et al. [<xref ref-type="bibr" rid="CR19">19</xref>]. It is also consistent with the Egyptian study of Tohamy et al. [<xref ref-type="bibr" rid="CR24">24</xref>], who reported that sensory symptoms initially were markedly associated with diagnostic delay due to symptom denial. Furthermore, it aligns with another Egyptian study that examined patients from upper Egypt. This study found a substantial variation in diagnostic delay of patients with motor compared to non-motor onset [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par44">The linear regression analysis revealed a significant correlation between diagnosis delay and increased disease severity. Uher et al. [<xref ref-type="bibr" rid="CR42">42</xref>] showed a significant correlation between diagnostic delays and increased levels of neurofilament light chain in the blood, which is a marker of neuronal damage. The negative impact of a delayed diagnosis on the outcome may be attributed to the ongoing progression of the disease, which exacerbates the occurrence of damage associated with the disease in the absence of proper treatment for an undetected condition. Timely intervention for MS can effectively control inflammation, hence potentially halting or even preventing the progression of neurodegeneration.</p><p id="Par45">The most compelling long-term evidence from clinical studies with participants in preliminary trials of interferon beta demonstrates a significant improvement in mortality rates in patients who initiated treatment a year or two earlier. Additionally, it had a discernible effect on mitigating disability [<xref ref-type="bibr" rid="CR43">43</xref>]. In addition, five-year follow-ups of early trials of natalizumab showed that patients in the initial treatment group had a lower EDSS score compared to those who initially received a placebo and started active treatment two years later [<xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par46">There is growing evidence indicating that presymptomatic patients (radiologically isolated syndrome) experience substantial neuronal damage even in the prodromal phase prior to diagnosis by MRI [<xref ref-type="bibr" rid="CR45">45</xref>]. Additionally, Cortese et al. [<xref ref-type="bibr" rid="CR46">46</xref>] assessed the cognitive performance of over 20,000 individuals and found that men who were later diagnosed with MS had worse cognitive scores compared to healthy individuals up to 2 years prior to experiencing their first clinical symptoms. These data indicate that waiting until the clinical disease begins to start treatment may not be early enough to stop the progression of physical and cognitive impairment.</p><p id="Par47">The sample size of this study is regarded as advantageous due to the fact that the prevalence of multiple sclerosis in Egypt is 25 cases per 100,000 individuals. In addition, we incorporated centers situated in key demographic regions of Egypt and conducted a comprehensive analysis of the significant clinical and sociodemographic characteristics exhibited by our patients that could potentially influence the objective of the study. The limitation of this study is the challenge of adequately determining the exact time of symptoms onset and confirmation of diagnosis, which may have introduced recall bias and influenced the results.</p></sec><sec id="Sec6"><title>Conclusion</title><p id="Par48">In our cohort study, MS patients with sensory symptoms or PPMS had the longest duration until diagnosis. These findings may prompt additional clinical assessment and investigation for patients experiencing psychiatric or non-specific neurological symptoms.</p><p id="Par49">Implementing educational and awareness initiatives in primary care, specialized MS centers, and optimized accelerated access routes to neurologists, can lead to an earlier diagnosis and improved outcomes.</p><p id="Par50">Our study emphasizes the correlation between the delay in diagnosing MS and various disease outcome measures, including disease severity and disability. Therefore, early diagnosis may improve outcomes for MS patients.</p><p id="Par51">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Correlation between diagnostic delay and Current EDSS (expanded disability status scale)</p></caption><graphic id="d33e1570" position="float" orientation="portrait" xlink:href="12883_2025_4172_Fig2_HTML.jpg"/></fig>
</p><p id="Par52">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Correlation between diagnostic delay and MSSS (multiple sclerosis severity scale)</p></caption><graphic id="d33e1580" position="float" orientation="portrait" xlink:href="12883_2025_4172_Fig3_HTML.jpg"/></fig>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to appreciate all participants as well as the hospital staff who contributed to the study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>S.R.: Methodology, Writing - original draft, Visualization, Investigation. N.A.H.: Conceptualization, Data curation, Writing - review &amp; editing. A.A. and B.H.F.: Writing - review &amp; editing. A.A.S.: conceptualization, methodology. A.M.H.: Writing - review &amp; editing. A.E.: Software, Visualization.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>There is no source of funding for the research.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par53">The study was approved from the Institutional Ethics Committee of the Faculty of Medicine, Kafrelsheikh University (MKSU 50-7-4) according to the ethical criteria of the Declaration of Helsinki. A Written informed consent was obtained from all participants, as well as from the parents or legal guardians of those under the age of 16, after explaining the study&#8217;s details, benefits, and potential risks.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par54">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par55">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>MS</term><def><p id="Par56">Multiple sclerosis</p></def></def-item><def-item><term>RR-MS</term><def><p id="Par57">Relapsing-remitting MS</p></def></def-item><def-item><term>EDSS</term><def><p id="Par58">Expanded Disability Status Scale</p></def></def-item><def-item><term>MSSS</term><def><p id="Par59">Multiple Sclerosis Severity Score</p></def></def-item><def-item><term>SPSS</term><def><p id="Par60">Statistical Package for the Social Sciences Software</p></def></def-item><def-item><term>SPMS</term><def><p id="Par61">Secondary progressive MS</p></def></def-item><def-item><term>PPMS</term><def><p id="Par62">Primary progressive MS</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Filippi</surname><given-names>M</given-names></name><name name-style="western"><surname>Bar-Or</surname><given-names>A</given-names></name><name name-style="western"><surname>Piehl</surname><given-names>F</given-names></name><etal/></person-group><article-title>Multiple sclerosis</article-title><source>Nat Rev Dis Prim</source><year>2018</year><volume>4</volume><fpage>43</fpage><pub-id pub-id-type="pmid">30410033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-018-0041-4</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Prim. 2018;4:43.<pub-id pub-id-type="pmid">30410033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-018-0041-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leray</surname><given-names>E</given-names></name><name name-style="western"><surname>Moreau</surname><given-names>T</given-names></name><name name-style="western"><surname>Fromont</surname><given-names>A</given-names></name><name name-style="western"><surname>Edan</surname><given-names>G</given-names></name></person-group><article-title>Epidemiology of multiple sclerosis</article-title><source>Rev Neurol</source><year>2016</year><volume>172</volume><fpage>3</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">26718593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurol.2015.10.006</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol. 2016;172:3&#8211;13.<pub-id pub-id-type="pmid">26718593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurol.2015.10.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Banwell</surname><given-names>BL</given-names></name><name name-style="western"><surname>Barkhof</surname><given-names>F</given-names></name><name name-style="western"><surname>Carroll</surname><given-names>WM</given-names></name><name name-style="western"><surname>Coetzee</surname><given-names>T</given-names></name><name name-style="western"><surname>Comi</surname><given-names>G</given-names></name><etal/></person-group><article-title>Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria</article-title><source>Lancet Neurol</source><year>2018</year><volume>17</volume><fpage>162</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">29275977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(17)30470-2</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162&#8211;73.<pub-id pub-id-type="pmid">29275977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(17)30470-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez</surname><given-names>O</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>V</given-names></name><name name-style="western"><surname>Arbizu</surname><given-names>T</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>G</given-names></name><name name-style="western"><surname>Bosca</surname><given-names>I</given-names></name><name name-style="western"><surname>Arroyo</surname><given-names>R</given-names></name><etal/></person-group><article-title>Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study)</article-title><source>J Neurol</source><year>2010</year><volume>257</volume><fpage>1500</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">20383518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-010-5560-1</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Fernandez O, Fernandez V, Arbizu T, Izquierdo G, Bosca I, Arroyo R, et al. Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study). J Neurol. 2010;257:1500&#8211;7.<pub-id pub-id-type="pmid">20383518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-010-5560-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>JR</given-names></name></person-group><article-title>The importance of early diagnosis of multiple sclerosis</article-title><source>J Manag Care Pharm</source><year>2004</year><volume>10</volume><fpage>S4</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">15253684</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Miller JR. The importance of early diagnosis of multiple sclerosis. J Manag Care Pharm. 2004;10:S4&#8211;11.<pub-id pub-id-type="pmid">15253684</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Derfuss</surname><given-names>T</given-names></name><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name></person-group><article-title>Evaluating the potential benefit of interferon treatment in multiple sclerosis</article-title><source>JAMA</source><year>2012</year><volume>308</volume><fpage>290</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">22797647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2012.8327</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Derfuss T, Kappos L. Evaluating the potential benefit of interferon treatment in multiple sclerosis. JAMA. 2012;308:290&#8211;1.<pub-id pub-id-type="pmid">22797647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2012.8327</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><collab>University of California - San Francisco</collab><name name-style="western"><surname>Team</surname><given-names>MS-EPIC</given-names></name><name name-style="western"><surname>Cree</surname><given-names>BA</given-names></name><name name-style="western"><surname>Gourraud</surname><given-names>PA</given-names></name><name name-style="western"><surname>Oksenberg</surname><given-names>JR</given-names></name><name name-style="western"><surname>Bevan</surname><given-names>C</given-names></name><name name-style="western"><surname>Crabtree-Hartman</surname><given-names>E</given-names></name><etal/></person-group><article-title>Long-term evolution of multiple sclerosis disability in the treatment era</article-title><source>Ann Neurol</source><year>2016</year><volume>80</volume><fpage>499</fpage><lpage>510</lpage><pub-id pub-id-type="pmid">27464262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24747</pub-id><pub-id pub-id-type="pmcid">PMC5105678</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">University of California - San Francisco, Team MS-EPIC, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016;80:499&#8211;510.<pub-id pub-id-type="pmid">27464262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24747</pub-id><pub-id pub-id-type="pmcid">PMC5105678</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Edan</surname><given-names>G</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Montalban</surname><given-names>X</given-names></name><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Hemmer</surname><given-names>B</given-names></name><etal/></person-group><article-title>The 11-year long-term follow-up study from the randomized BENEFIT CIS trial</article-title><source>Neurology</source><year>2016</year><volume>87</volume><fpage>978</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">27511182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000003078</pub-id><pub-id pub-id-type="pmcid">PMC5027814</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Kappos L, Edan G, Freedman MS, Montalban X, Hartung HP, Hemmer B, et al. The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016;87:978&#8211;87.<pub-id pub-id-type="pmid">27511182</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000003078</pub-id><pub-id pub-id-type="pmcid">PMC5027814</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kingwell</surname><given-names>E</given-names></name><name name-style="western"><surname>Leung</surname><given-names>AL</given-names></name><name name-style="western"><surname>Roger</surname><given-names>E</given-names></name><name name-style="western"><surname>Duquette</surname><given-names>P</given-names></name><name name-style="western"><surname>Rieckmann</surname><given-names>P</given-names></name><name name-style="western"><surname>Tremlett</surname><given-names>H</given-names></name><etal/></person-group><article-title>Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts</article-title><source>J Neurol Sci</source><year>2010</year><volume>292</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">20202651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2010.02.007</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Kingwell E, Leung AL, Roger E, Duquette P, Rieckmann P, Tremlett H, et al. Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci. 2010;292:57&#8211;62.<pub-id pub-id-type="pmid">20202651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2010.02.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrew</surname><given-names>J</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>RT</given-names></name><name name-style="western"><surname>Naismith, Anne</surname><given-names>H</given-names></name></person-group><article-title>Misdiagnosis of multiple sclerosis impact of the 2017 McDonald criteria on clinical practice</article-title><source>Cross Neurol Jan</source><year>2019</year><volume>92</volume><issue>1</issue><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000006583</pub-id><pub-id pub-id-type="pmcid">PMC6336166</pub-id><pub-id pub-id-type="pmid">30381369</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Andrew J, Solomon RT, Naismith, Anne H. Misdiagnosis of multiple sclerosis impact of the 2017 McDonald criteria on clinical practice. Cross Neurol Jan. 2019;92(1):26&#8211;33.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000006583</pub-id><pub-id pub-id-type="pmcid">PMC6336166</pub-id><pub-id pub-id-type="pmid">30381369</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Weinshenker</surname><given-names>BG</given-names></name></person-group><article-title>Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention</article-title><source>Curr Neurol Neurosci Rep</source><year>2013</year><volume>13</volume><fpage>403</fpage><pub-id pub-id-type="pmid">24142849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11910-013-0403-y</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Solomon AJ, Weinshenker BG. Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention. Curr Neurol Neurosci Rep. 2013;13:403.<pub-id pub-id-type="pmid">24142849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11910-013-0403-y</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Albanese M, sara zagaglia et al. 2016. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression. J Neuroinflammation. 2016; 13: 36.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12974-016-0502-1</pub-id><pub-id pub-id-type="pmcid">PMC4750170</pub-id><pub-id pub-id-type="pmid">26863878</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurtzke</surname><given-names>JF</given-names></name></person-group><article-title>Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)</article-title><source>Neurology</source><year>1983</year><volume>33</volume><fpage>1444</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">6685237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.33.11.1444</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444&#8211;52.<pub-id pub-id-type="pmid">6685237</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/wnl.33.11.1444</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roxburgh</surname><given-names>RH</given-names></name><name name-style="western"><surname>Seaman</surname><given-names>SR</given-names></name><name name-style="western"><surname>Masterman</surname><given-names>T</given-names></name><etal/></person-group><article-title>Multiple sclerosis severity score: using disability and disease duration to rate disease severity</article-title><source>Neurology</source><year>2005</year><volume>64</volume><issue>7</issue><fpage>1144</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15824338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.WNL.0000156155.19270.F8</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Roxburgh RH, Seaman SR, Masterman T, et al. Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology. 2005;64(7):1144&#8211;51.<pub-id pub-id-type="pmid">15824338</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.WNL.0000156155.19270.F8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khodaie</surname><given-names>F</given-names></name><name name-style="western"><surname>Moghadasi</surname><given-names>AN</given-names></name><name name-style="western"><surname>Hosseinnataj</surname><given-names>A</given-names></name><etal/></person-group><article-title>Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A National registry-based study</article-title><source>Clin Neurol Neurosurg</source><year>2024</year><volume>239</volume><fpage>108</fpage><lpage>221</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clineuro.2024.108221</pub-id><pub-id pub-id-type="pmid">38447483</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Khodaie F, Moghadasi AN, Hosseinnataj A, et al. Time interval between the onset of symptoms and diagnosis of multiple sclerosis and the influential factors: A National registry-based study. Clin Neurol Neurosurg. 2024;239:108&#8211;221.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clineuro.2024.108221</pub-id><pub-id pub-id-type="pmid">38447483</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghiasian</surname><given-names>M</given-names></name><name name-style="western"><surname>Faryadras</surname><given-names>M</given-names></name><name name-style="western"><surname>Mansour</surname><given-names>M</given-names></name><name name-style="western"><surname>Khanlarzadeh</surname><given-names>E</given-names></name><name name-style="western"><surname>Mazaheri</surname><given-names>S</given-names></name></person-group><article-title>Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990&#8211;2016</article-title><source>Acta Neurol Belg</source><year>2021</year><volume>121</volume><issue>1</issue><fpage>199</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">33180313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13760-020-01528-7</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ghiasian M, Faryadras M, Mansour M, Khanlarzadeh E, Mazaheri S. Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990&#8211;2016. Acta Neurol Belg. 2021;121(1):199&#8211;204.<pub-id pub-id-type="pmid">33180313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13760-020-01528-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thormann</surname><given-names>A</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>PS</given-names></name><name name-style="western"><surname>KochHenriksen</surname><given-names>N</given-names></name><name name-style="western"><surname>Laursen</surname><given-names>B</given-names></name><name name-style="western"><surname>Magyari</surname><given-names>M</given-names></name></person-group><article-title>Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality</article-title><source>Neurology</source><year>2017</year><volume>89</volume><issue>16</issue><fpage>1668</fpage><pub-id pub-id-type="pmid">28931645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000004508</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Thormann A, Sorensen PS, KochHenriksen N, Laursen B, Magyari M. Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology. 2017;89(16):1668.<pub-id pub-id-type="pmid">28931645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000004508</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Al Ma&#8217;ani</surname><given-names>MY</given-names></name><name name-style="western"><surname>Mahmoud</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Balkar</surname><given-names>YS</given-names></name><name name-style="western"><surname>Dwaik</surname><given-names>HA</given-names></name><etal/></person-group><article-title>Multiple sclerosis awareness in Jordan, and how does it affect the time of diagnosis</article-title><source>J Hosp Health Care Admin</source><year>2023</year><volume>7</volume><fpage>170</fpage></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Bahou Y, Al Ma&#8217;ani MY, Mahmoud LJ, Balkar YS, Dwaik HA, et al. Multiple sclerosis awareness in Jordan, and how does it affect the time of diagnosis. J Hosp Health Care Admin. 2023;7:170.</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aires</surname><given-names>A</given-names></name><etal/></person-group><article-title>Diagnostic delay of multiple sclerosis in a Portuguese population</article-title><source>Acta Med Port</source><year>2019</year><volume>32</volume><issue>4</issue><fpage>289</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">31067423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20344/amp.11187</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Aires A, et al. Diagnostic delay of multiple sclerosis in a Portuguese population. Acta Med Port. 2019;32(4):289&#8211;94.<pub-id pub-id-type="pmid">31067423</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20344/amp.11187</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mobasheri</surname><given-names>F</given-names></name><name name-style="western"><surname>Jaberi</surname><given-names>AR</given-names></name><name name-style="western"><surname>Hasanzadeh</surname><given-names>J</given-names></name><name name-style="western"><surname>Fararouei</surname><given-names>M</given-names></name></person-group><article-title>Multiple sclerosis diagnosis delay and its associated factors among Iranian patients</article-title><source>Clin Neurol Neurosurg</source><year>2020</year><volume>199</volume><fpage>106278</fpage><pub-id pub-id-type="pmid">33069931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clineuro.2020.106278</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Mobasheri F, Jaberi AR, Hasanzadeh J, Fararouei M. Multiple sclerosis diagnosis delay and its associated factors among Iranian patients. Clin Neurol Neurosurg. 2020;199:106278.<pub-id pub-id-type="pmid">33069931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clineuro.2020.106278</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Khedr EM, El Malky I, Hussein HB et al. Multiple sclerosis diagnostic delay and its associated factors in upper Egyptian patients. Sci Rep.3023; 13, 2249.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-023-28864-x</pub-id><pub-id pub-id-type="pmcid">PMC9908930</pub-id><pub-id pub-id-type="pmid">36754987</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Multiple sclerosis in. adults: management. Clinical guideline [CG186]. October 2014. [accessed 2017 Apr 11]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.nice.org.uk/guidance/cg186">https://www.nice.org.uk/guidance/cg186</ext-link></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Marrie</surname><given-names>RA</given-names></name><name name-style="western"><surname>Viswanathan</surname><given-names>S</given-names></name><name name-style="western"><surname>Correale</surname><given-names>J</given-names></name><name name-style="western"><surname>Magyari</surname><given-names>M</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>NP</given-names></name><name name-style="western"><surname>Saylor</surname><given-names>DR</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>W</given-names></name><name name-style="western"><surname>Rechtman</surname><given-names>L</given-names></name><name name-style="western"><surname>Bae</surname><given-names>E</given-names></name><name name-style="western"><surname>Shinohara</surname><given-names>R</given-names></name></person-group><article-title>King R, Laurson-Doube J and Helme A. Global barriers to the diagnosis of multiple sclerosis</article-title><source>Neurology</source><year>2023</year><volume>101</volume><issue>6</issue><fpage>e624</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">37321866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000207481</pub-id><pub-id pub-id-type="pmcid">PMC10424832</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Solomon AJ, Marrie RA, Viswanathan S, Correale J, Magyari M, Robertson NP, Saylor DR, Kaye W, Rechtman L, Bae E, Shinohara R. King R, Laurson-Doube J and Helme A. Global barriers to the diagnosis of multiple sclerosis. Neurology. 2023;101(6):e624&#8211;35.<pub-id pub-id-type="pmid">37321866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000207481</pub-id><pub-id pub-id-type="pmcid">PMC10424832</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Tohamy AA, Swelam MS, Abdelgawad DM, Aref HA. Causes of delayed diagnosis of multiple sclerosis in Egypt. QJM Int J Med. 2020;113.</mixed-citation></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marrie</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Changes in the ascertainment of multiple sclerosis</article-title><source>Neurology</source><year>2005</year><volume>65</volume><issue>7</issue><fpage>1066</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">16217060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000178891.20579.64</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Marrie RA, et al. Changes in the ascertainment of multiple sclerosis. Neurology. 2005;65(7):1066&#8211;70.<pub-id pub-id-type="pmid">16217060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000178891.20579.64</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">C&#225;rdenas-Robledo S, Lopez-Reyes L, Arenas-Vargas LE, Carvajal-Parra MS, Gu&#237;o-S&#225;nchez C. Delayed diagnosis of multiple sclerosis in a low prevalence country. Neurol Res 2021 43(7), 521&#8211;7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/01616412.2020.1866374</pub-id><pub-id pub-id-type="pmid">33357115</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Patti F, Chisari CG, Arena S, Toscano S, Finocchiaro C. Salvatore Lo Fermo, Maria Luisa Judica, Davide Maimone, Factors driving delayed time to multiple sclerosis diagnosis: Results from a population-based study, Multiple Sclerosis and Related Disorders.2022; Volume 57.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2021.103361</pub-id><pub-id pub-id-type="pmid">35158432</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grytten</surname><given-names>N</given-names></name><name name-style="western"><surname>Aarseth</surname><given-names>JH</given-names></name><name name-style="western"><surname>Lunde</surname><given-names>HMB</given-names></name></person-group><article-title>AlA 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County</article-title><source>Western NorwayJournal Neurol Neurosurg Psychiatry</source><year>2016</year><volume>87</volume><fpage>100</fpage><lpage>5</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2014-309906</pub-id><pub-id pub-id-type="pmcid">PMC4717445</pub-id><pub-id pub-id-type="pmid">25714916</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Grytten N, Aarseth JH, Lunde HMB. AlA 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County. Western NorwayJournal Neurol Neurosurg Psychiatry. 2016;87:100&#8211;5.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2014-309906</pub-id><pub-id pub-id-type="pmcid">PMC4717445</pub-id><pub-id pub-id-type="pmid">25714916</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosseinnataj</surname><given-names>A</given-names></name><name name-style="western"><surname>Nikbakht</surname><given-names>R</given-names></name><name name-style="western"><surname>Mousavinasab</surname><given-names>SN</given-names></name><name name-style="western"><surname>Eskandarieh</surname><given-names>S</given-names></name><name name-style="western"><surname>Sahraian</surname><given-names>MA</given-names></name><name name-style="western"><surname>Baghbanian</surname><given-names>SM</given-names></name></person-group><article-title>Factors associated with the number of months of delaying in multiple sclerosis diagnosis: comparison of count regression models</article-title><source>Curr J Neurol</source><year>2023</year><volume>22</volume><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">38011390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18502/cjn.v22i2.13330</pub-id><pub-id pub-id-type="pmcid">PMC10460919</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Hosseinnataj A, Nikbakht R, Mousavinasab SN, Eskandarieh S, Sahraian MA, Baghbanian SM. Factors associated with the number of months of delaying in multiple sclerosis diagnosis: comparison of count regression models. Curr J Neurol. 2023;22:65&#8211;71.<pub-id pub-id-type="pmid">38011390</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18502/cjn.v22i2.13330</pub-id><pub-id pub-id-type="pmcid">PMC10460919</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngwira</surname><given-names>LG</given-names></name><name name-style="western"><surname>Dowdy</surname><given-names>DW</given-names></name><name name-style="western"><surname>Khundi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Delay in seeking care for tuberculosis symptoms among adults newly diagnosed with HIV in rural Malawi</article-title><source>Int J Tuberc Lung Dis</source><year>2018</year><volume>22</volume><issue>3</issue><fpage>280</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">29471905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5588/ijtld.17.0539</pub-id><pub-id pub-id-type="pmcid">PMC5824850</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ngwira LG, Dowdy DW, Khundi M, et al. Delay in seeking care for tuberculosis symptoms among adults newly diagnosed with HIV in rural Malawi. Int J Tuberc Lung Dis. 2018;22(3):280&#8211;6.<pub-id pub-id-type="pmid">29471905</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5588/ijtld.17.0539</pub-id><pub-id pub-id-type="pmcid">PMC5824850</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>F</given-names></name><name name-style="western"><surname>Thompson</surname></name></person-group><article-title>E.Disparity in breast cancer late stage at diagnosis in Missouri: does rural versus urban residence matter?</article-title><source>J Racial Ethn Health Disparities</source><year>2016</year><volume>3</volume><issue>2</issue><fpage>233</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">27271063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40615-015-0132-9</pub-id><pub-id pub-id-type="pmcid">PMC6314175</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Williams F, Thompson. E.Disparity in breast cancer late stage at diagnosis in Missouri: does rural versus urban residence matter? J Racial Ethn Health Disparities. 2016;3(2):233&#8211;9.<pub-id pub-id-type="pmid">27271063</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40615-015-0132-9</pub-id><pub-id pub-id-type="pmcid">PMC6314175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yimer</surname><given-names>SA</given-names></name><name name-style="western"><surname>Bjune</surname><given-names>GA</given-names></name><name name-style="western"><surname>Holm-Hansen</surname></name></person-group><article-title>C.Time to first consultation, diagnosis and treatment of TB among patients attending a referral hospital in Northwest, Ethiopia</article-title><source>BMC Infect Dis</source><year>2014</year><volume>14</volume><issue>1</issue><fpage>19</fpage><pub-id pub-id-type="pmid">24410927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2334-14-19</pub-id><pub-id pub-id-type="pmcid">PMC3898386</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Yimer SA, Bjune GA, Holm-Hansen. C.Time to first consultation, diagnosis and treatment of TB among patients attending a referral hospital in Northwest, Ethiopia. BMC Infect Dis. 2014;14(1):19.<pub-id pub-id-type="pmid">24410927</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1471-2334-14-19</pub-id><pub-id pub-id-type="pmcid">PMC3898386</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kisiangani</surname><given-names>J</given-names></name><name name-style="western"><surname>Baliddawa</surname><given-names>J</given-names></name><name name-style="western"><surname>Marinda</surname><given-names>P</given-names></name><etal/></person-group><article-title>Determinants of breast cancer early detection for cues to expanded control and care: the lived experiences among women from Western Kenya</article-title><source>BMC Women&#8217;s Health</source><year>2018</year><volume>18</volume><issue>1</issue><fpage>81</fpage><pub-id pub-id-type="pmid">29859095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12905-018-0571-7</pub-id><pub-id pub-id-type="pmcid">PMC5984781</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kisiangani J, Baliddawa J, Marinda P, et al. Determinants of breast cancer early detection for cues to expanded control and care: the lived experiences among women from Western Kenya. BMC Women&#8217;s Health. 2018;18(1):81.<pub-id pub-id-type="pmid">29859095</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12905-018-0571-7</pub-id><pub-id pub-id-type="pmcid">PMC5984781</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Kaufmann M, Kuhle J, Puhan MA et al. Factors associated with time from first-symptoms to diagnosis and treatment initiation of multiple sclerosis in Switzerland. Multiple Scler J - Experimental Translational Clin. 2018;4(4).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2055217318814562</pub-id><pub-id pub-id-type="pmcid">PMC6293378</pub-id><pub-id pub-id-type="pmid">30559972</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eccles</surname><given-names>A</given-names></name></person-group><article-title>Debate and analysis delayed diagnosis of multiple sclerosis in males: May account for and dispel common Understandings of diferent MS types</article-title><source>Br J Gen Pract</source><year>2019</year><volume>69</volume><issue>680</issue><fpage>148</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">30819757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3399/bjgp19X701729</pub-id><pub-id pub-id-type="pmcid">PMC6400596</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Eccles A. Debate and analysis delayed diagnosis of multiple sclerosis in males: May account for and dispel common Understandings of diferent MS types. Br J Gen Pract. 2019;69(680):148&#8211;9.<pub-id pub-id-type="pmid">30819757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3399/bjgp19X701729</pub-id><pub-id pub-id-type="pmcid">PMC6400596</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaisey</surname><given-names>M</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>AS</given-names></name></person-group><article-title>Multiple sclerosis diagnostic delay and misdiagnosis</article-title><source>Neurol Clin</source><year>2024</year><volume>42</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">37980109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ncl.2023.07.001</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Kaisey M, Solomon AS. Multiple sclerosis diagnostic delay and misdiagnosis. Neurol Clin. 2024;42(1):1&#8211;13.<pub-id pub-id-type="pmid">37980109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ncl.2023.07.001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levin</surname><given-names>N</given-names></name><name name-style="western"><surname>Mor</surname><given-names>M</given-names></name><name name-style="western"><surname>Ben-Hur</surname><given-names>T</given-names></name></person-group><article-title>Patterns of misdiagnosis of multiple sclerosis</article-title><source>Isr Med Assoc J</source><year>2003</year><volume>5</volume><fpage>489</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">12901244</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Levin N, Mor M, Ben-Hur T. Patterns of misdiagnosis of multiple sclerosis. Isr Med Assoc J. 2003;5:489&#8211;90.<pub-id pub-id-type="pmid">12901244</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farber</surname><given-names>R</given-names></name><name name-style="western"><surname>Hannigan</surname><given-names>C</given-names></name><name name-style="western"><surname>Alcauskas</surname><given-names>M</given-names></name><name name-style="western"><surname>Krieger</surname><given-names>S</given-names></name></person-group><article-title>Emergency department visits before the diagnosis of MS</article-title><source>Mult Scler Relat Disord</source><year>2014</year><volume>3</volume><fpage>350</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">25876472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2013.11.004</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Farber R, Hannigan C, Alcauskas M, Krieger S. Emergency department visits before the diagnosis of MS. Mult Scler Relat Disord. 2014;3:350&#8211;4.<pub-id pub-id-type="pmid">25876472</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2013.11.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P&#233;loquin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Challenges in multiple sclerosis care: results from an international mixed-methods study</article-title><source>Mult Scler Relat Disord</source><year>2021</year><volume>50</volume><fpage>102854</fpage><pub-id pub-id-type="pmid">33690086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2021.102854</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">P&#233;loquin S, et al. Challenges in multiple sclerosis care: results from an international mixed-methods study. Mult Scler Relat Disord. 2021;50:102854.<pub-id pub-id-type="pmid">33690086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2021.102854</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palace</surname><given-names>J</given-names></name></person-group><article-title>Making the diagnosis of multiple sclerosis</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2001</year><volume>71</volume><fpage>ii3</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11701777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.71.suppl_2.ii3</pub-id><pub-id pub-id-type="pmcid">PMC1765569</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Palace J. Making the diagnosis of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2001;71:ii3&#8211;8.<pub-id pub-id-type="pmid">11701777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp.71.suppl_2.ii3</pub-id><pub-id pub-id-type="pmcid">PMC1765569</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willis</surname><given-names>MA</given-names></name><name name-style="western"><surname>Fox</surname><given-names>RJ</given-names></name></person-group><article-title>Progressive multiple sclerosis</article-title><source>Continuum</source><year>2016</year><volume>22</volume><fpage>785</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">27261682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/CON.0000000000000323</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Willis MA, Fox RJ. Progressive multiple sclerosis. Continuum. 2016;22:785&#8211;98.<pub-id pub-id-type="pmid">27261682</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/CON.0000000000000323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uher</surname><given-names>T</given-names></name><name name-style="western"><surname>Adzima</surname><given-names>A</given-names></name><name name-style="western"><surname>Srpova</surname><given-names>B</given-names></name><name name-style="western"><surname>Noskova</surname><given-names>L</given-names></name><name name-style="western"><surname>Mar&#233;chal</surname><given-names>B</given-names></name><name name-style="western"><surname>Maceski</surname><given-names>AM</given-names></name><name name-style="western"><surname>Krasensky</surname><given-names>J</given-names></name><name name-style="western"><surname>Stastna</surname><given-names>D</given-names></name><name name-style="western"><surname>Andelova</surname><given-names>M</given-names></name><name name-style="western"><surname>Novotna</surname><given-names>K</given-names></name><name name-style="western"><surname>Vodehnalova</surname><given-names>K</given-names></name><name name-style="western"><surname>Mot&#253;l</surname><given-names>J</given-names></name><name name-style="western"><surname>Friedova</surname><given-names>L</given-names></name><name name-style="western"><surname>Lindner</surname><given-names>J</given-names></name><name name-style="western"><surname>Ravano</surname><given-names>V</given-names></name><name name-style="western"><surname>Burgetova</surname><given-names>A</given-names></name><name name-style="western"><surname>Dusek</surname><given-names>P</given-names></name><name name-style="western"><surname>Fialova</surname><given-names>L</given-names></name><name name-style="western"><surname>Havrdova</surname><given-names>E</given-names></name><name name-style="western"><surname>Horakova</surname><given-names>D</given-names></name><name name-style="western"><surname>Kober</surname><given-names>T</given-names></name><name name-style="western"><surname>Kuhle</surname><given-names>J</given-names></name><name name-style="western"><surname>Vaneckova</surname><given-names>M</given-names></name></person-group><article-title>Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences</article-title><source>Multiple Scler J</source><year>2023</year><volume>29</volume><fpage>1437</fpage><lpage>51</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/13524585231197076</pub-id><pub-id pub-id-type="pmcid">PMC10580682</pub-id><pub-id pub-id-type="pmid">37840276</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Uher T, Adzima A, Srpova B, Noskova L, Mar&#233;chal B, Maceski AM, Krasensky J, Stastna D, Andelova M, Novotna K, Vodehnalova K, Mot&#253;l J, Friedova L, Lindner J, Ravano V, Burgetova A, Dusek P, Fialova L, Havrdova E, Horakova D, Kober T, Kuhle J, Vaneckova M. Diagnostic delay of multiple sclerosis: prevalence, determinants and consequences. Multiple Scler J. 2023;29:1437&#8211;51.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/13524585231197076</pub-id><pub-id pub-id-type="pmcid">PMC10580682</pub-id><pub-id pub-id-type="pmid">37840276</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodin</surname><given-names>DS</given-names></name><name name-style="western"><surname>Reder</surname><given-names>AT</given-names></name><name name-style="western"><surname>Ebers</surname><given-names>GC</given-names></name><etal/></person-group><article-title>Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN&#946;-1b trial</article-title><source>Neurology</source><year>2012</year><volume>78</volume><fpage>1315</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">22496198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182535cf6</pub-id><pub-id pub-id-type="pmcid">PMC3335454</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN&#946;-1b trial. Neurology. 2012;78:1315&#8211;22.<pub-id pub-id-type="pmid">22496198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182535cf6</pub-id><pub-id pub-id-type="pmcid">PMC3335454</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Connor</surname><given-names>P</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>A</given-names></name><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><etal/></person-group><article-title>Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study</article-title><source>Neurology</source><year>2014</year><volume>83</volume><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">24898925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000000541</pub-id><pub-id pub-id-type="pmcid">PMC4114173</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">O&#8217;Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study. Neurology. 2014;83:78&#8211;86.<pub-id pub-id-type="pmid">24898925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000000541</pub-id><pub-id pub-id-type="pmcid">PMC4114173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjornevik</surname><given-names>K</given-names></name><name name-style="western"><surname>Munger</surname><given-names>KL</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M</given-names></name><name name-style="western"><surname>Barro</surname><given-names>C</given-names></name><name name-style="western"><surname>Healy</surname><given-names>BC</given-names></name><name name-style="western"><surname>Niebuhr</surname><given-names>DW</given-names></name><etal/></person-group><article-title>Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis</article-title><source>JAMA Neurol</source><year>2020</year><volume>77</volume><issue>1</issue><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">31515562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.3238</pub-id><pub-id pub-id-type="pmcid">PMC6745051</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Bjornevik K, Munger KL, Cortese M, Barro C, Healy BC, Niebuhr DW, et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 2020;77(1):58&#8211;64.<pub-id pub-id-type="pmid">31515562</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.3238</pub-id><pub-id pub-id-type="pmcid">PMC6745051</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortese</surname><given-names>M</given-names></name><name name-style="western"><surname>Riise</surname><given-names>T</given-names></name><name name-style="western"><surname>Bjornevik</surname><given-names>K</given-names></name><name name-style="western"><surname>Bhan</surname><given-names>A</given-names></name><name name-style="western"><surname>Farbu</surname><given-names>E</given-names></name><name name-style="western"><surname>Grytten</surname><given-names>N</given-names></name><etal/></person-group><article-title>Preclinical disease activity in multiple sclerosis: a prospective study of cognitive performance prior to first symptom</article-title><source>Ann Neurol</source><year>2016</year><volume>80</volume><issue>4</issue><fpage>616</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">27554176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24769</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Cortese M, Riise T, Bjornevik K, Bhan A, Farbu E, Grytten N, et al. Preclinical disease activity in multiple sclerosis: a prospective study of cognitive performance prior to first symptom. Ann Neurol. 2016;80(4):616&#8211;24.<pub-id pub-id-type="pmid">27554176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.24769</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>